BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cerezo-manchado JJ, Navarro-almenzar B, Elvira-ruiz G, García-candel F, Flores-blanco PJ, Caro-martínez C, Manzano-fernández S, García-iniesta N, Sánchez-garcía J, Cabañas-perianes V, Moraleda-jiménez J. Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke. Future Cardiology 2018;14:31-7. [DOI: 10.2217/fca-2018-0024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Navarro-almenzar B, Cerezo-manchado JJ, Caro-martinez C, García-candel F, Flores Blanco PJ, Ruiz GE, Andreu Cayuelas JM, Montoya FA, Cascales A, Lova Navarro A, García Alberola A, Andrés Pascual Figal D, Bailen Lorenzo JL, Manzano-fernández S. Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: Refase Registry. Current Medical Research and Opinion 2019;35:2035-41. [DOI: 10.1080/03007995.2019.1647735] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
2 Fernández MS, Marín F, Rafols C, Arribas F, Barrios V, Cosín-Sales J, Sánchez MA; the EMIR Study Investigators:. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). J Comp Eff Res 2021;10:583-93. [PMID: 33787316 DOI: 10.2217/cer-2020-0286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]